

Personalized Computational Modeling Identifies Embolic Stroke of Undetermined Source Patients with Potential Arrhythmic Substrate

Savannah F. Bifulco,¹ Griffin D. Scott,¹ Sakher Sarairah,² Zeinab Birjandian,^{2,5}

Caroline H. Roney,³ Steven A. Niederer,³ Christian Mahnkopf,⁴ Peter Kuhnlein,⁴

Marcel Mitlacher,⁴ David Tirschwell,⁵ W. T. Longstreth Jr,^{5,6} Nazem Akoum,^{2} Patrick M. Boyle^{1,7,8*}*

1: Department of Bioengineering, University of Washington, Seattle, WA, USA.

2: Division of Cardiology, University of Washington, Seattle, WA, USA.

3: School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.

4: Department of Cardiology, Klinikum Coburg, Coburg, Germany.

5: Department of Neurology, University of Washington, Seattle, WA, USA.

6: Department of Epidemiology, University of Washington, Seattle, WA, USA.

7: Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA.

8: Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA.

***: Corresponding authors:**

PM Boyle; email: pmjboyle@uw.edu; mail: Foegen N310H UW Mailbox 355061, Seattle WA 98195, USA; OR,
N Akoum; email: nakoum@cardiology.washington.edu; mail: 1959 N Pacific St, Seattle WA 98115, USA

Word count, excluding Materials and Methods, References, and Figure Legends: 4342

Competing Interests: None declared

26 Abstract

27 Late-gadolinium enhanced (LGE)-MRI has revealed atrial fibrotic remodeling in embolic stroke of undetermined
28 source (ESUS) patients comparable to that observed in atrial fibrillation (AFib) patients. Here, we use computational
29 modeling to understand why fibrosis in ESUS does not cause arrhythmia. Left atrial (LA) models were reconstructed
30 via a standardized process and simulations were conducted to probe the fibrotic substrate's capacity to sustain
31 reentrant drivers (RD). RD-perpetuated arrhythmia was observed in 23/45 (51%) ESUS and 28/45 (62%) AFib
32 models. LA models in which RDs were inducible had significantly more fibrosis than those which were non-inducible
33 ($16.8 \pm 5.04\%$ vs. $10.19 \pm 3.14\%$; $P < 0.0001$); however, between the specific subsets of inducible ESUS and AFib
34 models, there was no difference in fibrosis burden ($P = 0.068$). Thus, within our modeling framework, pro-arrhythmic
35 properties of fibrosis in ESUS and AFib are indistinguishable, suggesting many ESUS patients have latent fibrotic
36 substrate that may be a potential future source of arrhythmogenicity.

37

38 Introduction

39 Atrial fibrillation (AFib) is the most common cardiac arrhythmia, affecting 1-2% of the world's
40 population and significantly contributing to worldwide morbidity and mortality (1). The primary source of
41 AFib-related mortality is stroke, with around 20% of all ischemic strokes occurring in AFib patients (1).
42 Sub-clinical AFib is implicated as a potential cause of embolic stroke of undetermined source (ESUS),
43 and the current course of clinical care following ESUS is to look for evidence of AFib via an external
44 monitor, an implanted loop recorder, or other forms of wearable monitoring devices. If AFib is diagnosed,
45 treatment with oral anticoagulants is started to mitigate the possibility of recurrent stroke (2). Clinical
46 studies have shown that AFib has been detected in only 30% of patients with long-term rhythm monitoring
47 (3). This creates a frustrating problem for clinicians: in the wake of ESUS events, it is impossible to know
48 which individuals should be treated as high-risk for AFib and therefore monitored accordingly.

49 Recent evidence from clinical studies suggests that the left atrial fibrosis burden measured by late
50 gadolinium enhanced (LGE)-MRI is as high in ESUS patients as in AFib patients without stroke (4). This
51 finding supports the hypothesis that atrial fibrosis is an element of the causal pathway for stroke, through
52 an atrial cardiopathy, and independent of AFib. The absence of AFib despite the presence of a fibrotic
53 substrate is intriguing and one potential explanation is that ESUS patients have pro-arrhythmic fibrotic
54 substrate but lack the triggers needed to initiate arrhythmia. Another potential explanation is that the
55 fibrosis present in ESUS patients is not pro-arrhythmic. Patient-derived computational modeling of atrial
56 arrhythmias is uniquely poised to test these hypotheses. Previously, personalized atrial models have
57 been used to assess arrhythmogenic propensity of fibrotic substrate and predict AFib ablation targets (5,
58 6). Applying the same approach, we can determine if, in the presence of appropriate triggers, fibrotic
59 remodeling in ESUS patients has the fundamental capacity to harbor reentrant arrhythmic activity.

60 Thus, we present a large-scale computational study to ascertain whether the fibrotic substrate
61 with the potential to perpetuate AFib-sustaining reentrant drivers (RDs) exists in ESUS patients. Our
62 hypothesis is that a pre-clinical AFib substrate, attributed to a pattern of fibrotic atrial remodeling that is
63 conducive to RD perpetuation, exists in ESUS patients. By conducting simulations in models derived
64 from LGE-MRI, we can begin to understand potential pro-arrhythmic properties of atrial fibrosis in ESUS

65 patients. The study thus provides insights on the role of atrial fibrosis as a pathophysiological nexus
66 between AFib and stroke.

67 Results

68 Patient Characteristics

69 Ninety patient-derived models were included in our analysis: 45 post-stroke ESUS and 45 pre-
70 ablation AFib patients. Demographic information about both patient groups is provided in Table 1. There
71 was a significant difference in LA surface area; however, the trend towards higher body mass index (BMI)
72 in AFib patients and the lack of difference in LA volume index between the two groups suggests the latter
73 trend (i.e., higher surface area in AFib) would be lessened if the values were normalized to body surface
74 area. LA fibrosis burden was not significantly different between ESUS ($13.6 \pm 6.2\%$) and AFib patients
75 ($14.2 \pm 4.5\%$) ($P=0.91$), consistent with previous findings (4).


	ESUS (N=45)	AFib (N=45)	P value
Age, y	60±16	62±12	0.504
Female, %	44.0%	32.8%	0.275
BMI, kg/m ²	27.6±4.3	29.5±5.9	0.08
CHA ₂ DVASc score	2.0	1.9	0.345
CHF, n	14.3%	18.4%	0.599
Hypertension, n	68.5%	61.2%	0.468
Diabetes mellitus, n	20.4%	12.2%	0.292
CAD, n	18.4%	18.4%	1.000
Smoking, n	32%	28%	0.679
LA fibrosis, %	13.6±6.2%	14.2±4.5%	0.91
LA surface area, cm ²	109±26	134±40	0.0007
LA volume index, mL/m ²	60±29	57±26	0.607

76 **Table 1.** Patient characteristics in ESUS and AFib groups.

77 Patient-derived model in silico AFib induction and fibrosis quantification


78 Personalized LA bilayer models were generated for all ESUS and AFib patients. Examples of
79 physiological detail incorporated in models can be seen in Fig. 1, including patient-specific patterns of
80 fibrotic remodeling, realistic atrial fiber orientations, and locations of electric pacing sites; further detail
81 can be found in the Methods section. Rapid electric stimulation caused RD-sustained arrhythmia in 28 of
82 45 AFib models (62.2%) and 23 of 45 ESUS models (51.1%). Thus, the capability of the fibrotic substrate
83 to sustain RDs was not significantly different between the two groups ($P=0.39$, Fig. 2A). ESUS and AFib
84 patients were then sorted by amount of global LA fibrosis and arranged into quartiles. For five patients

85 (21.7%) in the first quartile (fibrosis<9.75%), six patients (29.0%) in the second quartile (fibrosis<12.6%),
 86 nineteen (79.2%) patients in the third quartile (fibrosis<17.45%), and twenty-one (95.5%) patients in the
 87 top quartile, simulations in the corresponding LA model revealed at least one pacing site for which
 88 stimulation produced an episode of RD-sustained arrhythmia (Fig. 2B).



89

90 **Figure 1** Model generation (A) Reconstruction of LA geometry with anatomical features labelled
 91 (RIPV/RSPV/LIPV/LSPV, right/left inferior/superior pulmonary veins; LAA, LA appendage). The LA is modeled as
 92 a bilayer comprising nested endocardial and epicardial shells linked in both fibrotic and non-fibrotic regions by 1D
 93 linear elements. (B) LA fiber orientations for the endocardium and epicardium, mapped from human atlas geometry
 94 as described in Methods. (C) AFib trigger sites as pacing sites (posterior/anterior LIPV, LSPV, RSPV, RIPV, LAA
 95 base, mitral valve annulus and posterior wall). (D) Regions of the LA generated as described in methods: (1) atrial
 96 floor, (2) anterior wall and LAA, (3) posterior wall, (4) left PVs, (5) right PVs.




97

98 **Figure 2** Summary of patient-derived model fibrosis with respect to RD inducibility. (A) Histogram of AFib (28/45)
99 and ESUS (23/45) inducible patients. Inducibility was not significantly different by χ^2 test. (B) Patients with ESUS
100 and AFib arranged by percentage of LA fibrosis. Dotted lines indicate the quartiles of fibrosis observed for all 90
101 patients. Circles are indicative of stable reentry observed in the model from at least one pacing site after *in silico*
102 pacing protocol. Triangles indicate no RDs after pacing from all 15 pacing sites independently. Cases that lacked
103 RDs despite high fibrosis (inset I) or were inducible despite low fibrosis (inset II) are highlighted.


104 To explore potential pro-arrhythmic substrate properties in ESUS and AFib, we analyzed fibrosis
105 burden in the sub-groups of each cohort in which RD-sustained arrhythmias were inducible and non-
106 inducible (Fig. 3A). Fibrosis burden was not significantly different between ESUS and AFib with ($P=0.068$,
107 confidence interval; CI: [-0.2, 6.1], Fig. 3A) or without induced reentry ($P=0.58$, CI: [-2.4, 1.5], Fig. 3A).
108 However, when fibrosis burdens for inducible and non-inducible models were aggregated across ESUS
109 and AFib groups, a significant difference was evident (Fig. 3A; $16.8 \pm 5.04\%$ vs. $10.19 \pm 3.14\%$;
110 $P<0.0001$, CI: [4.4, 8.3]).

111 We also investigated potential differences in the number of unique RDs and the number of AFib
112 triggers that induced reentry in each patient-derived model. In all 51 inducible models, the median number
113 of unique RDs was 1.5 for AFib and 2 for ESUS models (range for both groups: 1-5). There was no
114 significant difference in the number of unique reentrant morphologies per model between the two groups
115 (Fig. 3B, $P=0.79$), CI: $[-1.6 \times 10^{-5}, 1]$. The number of unique RDs was positively correlated with atrial
116 fibrosis burden (Fig. 3C, $R=0.69$, $P<0.0001$). For all RD-inducible cases, the median number of
117 stimulation sites from which rapid pacing led to RD formation was 2.5 for AFib and 3 for ESUS models
118 (AFib range: 1-11; ESUS range: 1-7). No significant difference was found in the number of pacing sites
119 that induced reentry per model between AFib and ESUS (Fig. 3D, $P=0.98$, CI [-1,1]). The number of RD
120 inducing pacing sites was also significantly correlated with fibrosis burden (Fig. 3E, $R=0.67$, $P<0.0001$).



121

122 **Figure 3** Summary of RD characteristics between ESUS and AFib models. (A) Boxplot of fibrosis percentage in
 123 ESUS and AFib models where reentry was induced (ESUS: N=23, IQR=8.1; AFib: N=28, IQR=5.95) and where
 124 reentry was not induced (ESUS: N=22, IQR=4.98; AFib N=17, IQR=3.5). Across ESUS and AFib models, fibrosis
 125 burden for RD inducible and RD non-inducible models was significantly different ($P < 0.0001$). (B) Boxplot of number
 126 of unique reentrant morphologies elicited by all 15 pacing sites ($P = 0.79$). (C) Correlation plot of fibrosis vs number
 127 of RDs ($R = 0.69$, $P < 0.0001$) (D) Boxplot of the number of pacing sites which induced reentry ($P = 0.98$) (E) Correlation
 128 plot of fibrosis vs number of pacing sites that induced reentry ($R = 0.67$, $P < 0.0001$).




129

130 **Figure 4.** Maps of fibrotic tissue distribution (left) and activation time (right) for ESUS and AFib models in which
 131 pacing succeeded (rows 1-2) or failed (row 3) to induce RD-driven arrhythmia. Black arrows indicate directions of
 132 wavefront propagation in RDs. Double lines indicate sites of conduction block. Black-shaded regions in activation
 133 maps indicate locations where activation did not occur during the analysis interval. (A) ESUS model with 10.8%
 134 fibrosis and reentry inferior to LIPV. (B) ESUS model with 10.0% fibrosis and reentry on anterior wall. (C) ESUS
 135 model with 19.4% fibrosis with wavefront termination through fibrosis on posterior wall. (D) AFib model with 9.0%
 136 fibrosis and reentry observed adjacent to RIPV on posterior wall. (E) AFib model with 24.1% fibrosis and reentry
 137 observed inferior to the LIPV and on posterior wall. (F) AFib model with 12.3% fibrosis with wavefront collision on
 138 posterior wall.

139 Arrhythmia Dynamics

140 Analysis of simulated reentry episodes revealed no qualitative differences in arrhythmia dynamics
141 between AFib and ESUS models. Figure 4 shows examples of RD-perpetuated *in silico* arrhythmia and
142 instances where stimulation failed to induce reentry for both groups. Of note, this figure highlights two
143 inducible low-fibrosis ESUS models (Fig. 4A: 10.8% fibrosis, RD near the LIPV; Fig. 4B: 10.0% fibrosis,
144 RD in anterior wall) and a non-inducible high-fibrosis ESUS model (Fig. 4C: 19.4% fibrosis). In the latter
145 case, dense fibrosis on the posterior wall resulted in conduction block as indicated. Similarly, Figs. 4D
146 and 4E present examples of RD-driven arrhythmia in AFib models (9.0% and 24.1% fibrosis,
147 respectively), and Fig. 4F shows an AFib model (12.3% fibrosis) in which reentry was not induced due to
148 wavefront collision in the posterior wall region. Overall, this analysis shows that both ESUS and AFib
149 models exhibited activation patterns consistent with previous definitions of RD-driven arrhythmia;
150 examples of inducible low-fibrosis and non-inducible high-fibrosis models emphasize that fibrosis burden
151 alone is an insufficient predictor for a potential arrhythmic substrate.


152 For 50/51 inducible models, AFib was driven by persistent singular RDs. In one AFib model we
153 observed unique arrhythmia dynamics previously undocumented in atrial simulations, best described as
154 dual RD feedback and characterized by interaction between two distinct wavefronts wherein one follows
155 in the wake of another (Fig. 5 and Supplemental Video 1). Reentry appeared to occur as a result of a
156 large central refractory region arising from wavefront collision adjacent to the RIPV on the septal face.
157 This reentry morphology was stable for the duration of the simulation.



158

159 **Figure 5.** Sequential activation maps showing one RD cycle of dual RD feedback viewed from posterior (top) and
160 anterior (bottom) perspectives. Black-shaded region indicate locations where activation did not occur during the

161 analysis interval. Activation maps at 5450ms progress to 5900ms in increments of 150ms. Two distinct wavefronts
 162 (labeled 1 and 2 in the panels above) exist in this form of reentry and “chase” after one another for duration of the
 163 simulation. See also Supplemental Video 1.



164

165 **Figure 6.** Summary of IdS and RD localization characteristics. (A) Region-wise IdS for both ESUS and AFib LA
 166 models (B) Heat map of the regions in which triggers are most likely to induce arrhythmias depicted as
 167 representative ESUS and AFib models. (C) Histogram of RDs across all AFib and ESUS models binned by
 168 localization to specific LA regions. (D) Heat map of regions in which RDs are most likely to localize depicted as
 169 representative ESUS and AFib models.

170 **Properties of RD Localization**

171 As described in Methods, each model was automatically subdivided into five anatomical regions
172 (see schematic illustrations in Fig. 1D and Supplementary Fig. 1) and region-wise inducibility score
173 analysis (IdS, as described in Methods) was used to gauge likelihood of RD induction in response to
174 rapid electrical stimulation from different locations in the LA. While ESUS and AFib models had a
175 statistically similar pattern of inducibility rates ($P=0.73$, by χ^2 test), stimulation from the posterior wall was
176 ~3 times more likely to induce RDs in AFib models than ESUS models (Fig. 6A, IdS = 8 vs IdS = 3). In
177 other words, with all other factors held equal, our simulations suggest that triggered activity in the
178 posterior wall may be more likely to initiate reentrant arrhythmia in AFib patients compared to ESUS
179 patients. The same IdS values plotted in Fig. 6A were mapped onto representative LA models to facilitate
180 visual comparison of regional sensitivity to rapid pacing (Fig. 6B). Next, we considered the number of
181 unique RD localization sites in each LA region across the different model groups (i.e., AFib vs. ESUS).
182 The LPV region was most likely to harbor RDs in the AFib cohort (Fig. 6C, N=17). In the ESUS cohort,
183 the atrial floor was the most likely region to contain an RD (N=12), whereas in the AFib cohort this was
184 one of the least likely locations to harbor RDs (Fig. 6C, N=6). Of special note for the ESUS cohort, the
185 atrial floor was both the most sensitive to rapid pacing in terms of RD initiation and the most likely area
186 of RD localization (Fig. 6D). The association between the type of model (ESUS vs AFib) and RD
187 localization was not significant ($P=0.29$, χ^2 test).

188 **Discussion**

189 This study used a novel computational modeling approach to shed new light on the role of the
190 fibrotic atrial substrate in the potential for initiation and perpetuation of reentry in ESUS patients. In
191 models reconstructed from 45 post-stroke ESUS and 45 pre-ablation AFib patients, we showed that the
192 AFib and ESUS groups did not differ significantly in: (i) the propensity of the fibrotic substrate to sustain
193 RDs in response to simulated burst pacing; (ii) the LA fibrotic burden of RD-inducible models or RD-free
194 models; and (iii) the reentrant driver localization or the region-wise inducibility. This is the first study to
195 use computational modeling and simulation to assess potential pro-arrhythmic capacity of LA fibrosis in
196 ESUS patients. Moreover, to the best of our knowledge, this is the largest cohort ever studied via

197 computational analysis of atrial electrophysiology in models derived from LGE-MRI, exceeding the
198 number of patients (N=50) in the former largest study (7) by a factor of ~1.8.

199 **Inducibility of reentry and fibrosis quantification in patient-derived atrial models**

200 Experimental findings have shown that atrial fibrosis results in changes that promote reentry (8,
201 9), but the exact mechanism of this connection is not fully understood. Previous modeling studies have
202 linked RD localization to specific spatial patterns of fibrotic remodeling in AFib (5, 10). Recent clinical
203 findings indicate that atrial fibrosis burden does not differ significantly between AFib and ESUS patients,
204 and yet (by definition) ESUS patients do not demonstrate AFib at the time of stroke or during ambulatory
205 monitoring (4). Given the findings summarized above, a potential explanation is that, notwithstanding the
206 fact that ESUS patients have substantial fibrosis, the particular *spatial distribution* of fibrotic remodeling
207 in their atria is not conducive to arrhythmia perpetuation. Our findings suggest that this is likely not the
208 case. From the standpoint of computational models derived from patient LGE-MRI scans, fibrotic
209 substrate in individuals with ESUS is indistinguishable from that in patients with AFib in terms of the
210 fundamental capacity to sustain RDs. Reentrant arrhythmias were induced in 28/45 AFib models and
211 23/45 ESUS models (Fig. 2A). Across the combined set of 51 inducible models from both cohorts, we
212 found that high fibrosis models were more likely to exhibit RDs irrespective of whether they corresponded
213 to ESUS or AFib patients. This correlation has been characterized in prior AFib modeling studies (5, 6)
214 and is consistent with established clinical thinking regarding the relationship between fibrosis and AFib
215 outcomes (11). Notably, we did observe several cases in which models defied inducibility expectations
216 based on fibrosis alone. Such models exhibited RDs despite low fibrosis or were non-inducible despite
217 high fibrosis. This observation confirms that, as observed previously in analogous AFib modeling studies
218 (5, 6), assessment of raw fibrosis burden LGE-MRI scans alone is insufficient to fully characterize
219 arrhythmogenic capacity of potentially pro-arrhythmic substrate in ESUS.

220 Consistent with the goal of this research to understand the contribution of fibrotic substrate to
221 potential RD formation in ESUS, we purposefully excluded arrhythmias perpetuated by other
222 mechanisms from our study design (e.g., self-sustaining activity driven solely by focal sources). Potential
223 contributions from the right atrium (RA) were also excluded, since only the LA was segmented from LGE-

224 MRI as part of the clinical workflow. Either of these factors may explain the absence of simulated
225 arrhythmia in 17 of 45 AFib models, many of which had very little LA fibrosis (i.e., AFib in these individuals
226 might have been predominantly focal in nature or sustained by RDs in the RA). This rate of inducibility is
227 consistent with previous studies (e.g., 13 out of 20 in computational models reconstructed from LGE-MRI
228 scans of persistent AFib patients) (5), supporting the notion that LA fibrosis is associated with increased
229 arrhythmia inducibility but fails to tell the whole story. Importantly, neither of these model constraints
230 repudiates the central finding of our study, which suggests there is no difference between ESUS and
231 AFib patients in terms of the fundamental capacity of the fibrotic substrate to potentially harbor RDs.

232 **Reentrant driver localization dynamics and morphology in patient-derived atrial models**

233 As discussed above, our qualitative findings suggest that ESUS patients' fibrotic substrate is no
234 different than that of AFib patients in terms the capacity to sustain RDs per se. We performed additional
235 analysis to assess whether specific consequences of fibrotic remodeling influenced any characteristics
236 of RD inducibility in different ways for simulations in models corresponding to ESUS vs. AFib patients.
237 First, we found that there was no significant difference in global fibrosis burden between the 28 inducible
238 AFib models and the 23 inducible ESUS models (Fig. 3A). This finding suggests that intrinsic pro-
239 arrhythmic characteristics of the fibrotic substrate in ESUS and AFib patients are indistinguishable, which
240 is a key finding of this study. Given this result, one potential alternative explanation for the lack of
241 arrhythmia in ESUS patients is a lack of suitable triggers, despite an abundance of fibrotic substrate on
242 par with that observed in AFib. The plausibility of this explanation is strengthened by the fact that the
243 pacing sites from which episodes of reentry were induced in our study were based on common AFib
244 trigger sites as identified in a recent clinical study (12); this is in contrast to previous modeling studies,
245 which simulated triggered activity from evenly-distributed atrial sites (6). However,, the premise of this
246 aspect of our work was not to assess an absence of triggers, but instead ask the following: if the atria of
247 these ESUS patients were subjected to the same type of triggered activity known to occur in typical AFib
248 patients, is it possible the result be would sustained arrhythmia? In more than half of the cohort (23/45),
249 our analysis suggests that the answer is yes.

250 A potential implication of our study is that in AFib patients, pathological changes in geometry,
251 specifically increased LA surface area (134 ± 40 cm² for AFib vs. 109 ± 26 cm² for ESUS; $P=0.0007$; see
252 Table 1), and fibrotic remodeling may interact synergistically to promote RD formation. Other
253 measurements (BMI, LA volume index) suggest this difference might be abolished by normalizing these
254 values to body surface area. However, we opted to present absolute LA surface area values since a
255 relevant metric for arrhythmia perpetuation is effective heart size (i.e., ratio between absolute heart size
256 and cardiac wavelength) (13). In effect, larger effective heart size implies that reentrant wavefronts have
257 more "elbow room" to establish and anchor themselves, increasing the likelihood of sustained RD
258 occurrence. Thus, this may explain the trend towards higher burden of fibrosis in inducible ESUS models
259 vs. inducible AFib models (Fig. 3A, $P=0.068$). Since ESUS patients lack the anatomical LA remodeling
260 observed in AFib patients, a higher threshold of fibrotic tissue may be necessary in order for RD-driven
261 arrhythmia to be even theoretically possible. More work is needed to concretely validate this finding.

262 Further analysis was performed to probe potential differences between ESUS and AFib patients
263 that went beyond consideration of RD inducibility as a binary variable. Specifically, we found no significant
264 difference ($P=0.79$) in the number of unique model-predicted RDs between ESUS and AFib (range for
265 both groups: 1-5; Fig. 3B). Instead, the number of unique RDs was highly correlated (Fig. 3C, $R=0.69$,
266 $P<0.0001$) with LA fibrosis burden, which is consistent with the concept that high fibrosis models are
267 more likely to exhibit RDs. Secondly, analysis of the number of pacing sites that induced RDs revealed
268 high variability (range: 0-11 out of 15), but again the ESUS and AFib groups were similar in this regard
269 (Fig. 3D, $P=0.98$). This variable was also correlated to LA fibrosis burden ($R=0.67$, $P<0.0001$), suggesting
270 greater fibrotic remodeling leads to susceptibility to pacing-induced reentry by triggered activity from a
271 larger number of locations. This finding further substantiates our principal claim that no significant
272 differences exist between the detected fibrotic substrate in ESUS and AFib, in that it holds true for the
273 substrate's capacity to sustain reentry and its susceptibility to triggered activity. The general implication
274 is that in the presence of simulated triggered activity, both of these characteristics are closely linked to
275 global fibrosis burden.

276 RDs identified by non-invasive electrocardiographic imaging (ECGI) and *in silico* phase singularity
277 identification have been shown to co-localize with fibrosis boundary zones identified by LGE-MRI (5, 14-
278 16). RD localization dynamics in this study were consistent with these findings, as illustrated by
279 representative LA fibrotic tissue distributions and corresponding RD activation patterns in Fig. 4. RD
280 morphology in this study, for both AFib and ESUS models, largely corroborated previous findings
281 – arrhythmia episodes were perpetuated by one RD at a time, with activity in the periphery including
282 conduction block, transient reentry, and wavefront collision (5, 6). There was one noteworthy exception,
283 which was the dual reciprocating RD interaction documented in Fig. 5, in which a region of conduction
284 block formed dynamically in the myocardial region between the two circulating wavefronts. Similar
285 excitation sequences have been documented previously in embryonic chick cardiac cells (17) and in
286 patients with atypical flutter (18). It is unclear why we observed this behavior for the first time in this study
287 despite the fact that over 100 episodes of RD-driven arrhythmia have been simulated in dozens of
288 similarly constructed models (5, 6, 19). A potential explanation is the use of increased tissue conductivity
289 in the present study, resulting in faster conduction velocity.

290 **Insights from analysis of RD inducibility and localization by LA region**

291 Our findings thus far demonstrate that the properties of simulated RDs are indistinguishable
292 between ESUS and AFib. We then performed region-wise analysis to assess any systematic differences
293 in the spatial distribution of pro-arrhythmic fibrosis that could render certain regions more susceptible to
294 either triggered activity or RD-localization. Even when analyzing the atria by distinct regions, we found
295 that the spatial properties of the fibrotic substrate between AFib and ESUS patients are not intrinsically
296 different. ESUS and AFib models had no significant association to either reentrant driver localization or
297 region-wise inducibility ($P=0.73$ and $P=0.29$, by χ^2 test). However, our region-wise analysis (Fig. 6) did
298 yield several noteworthy findings that suggest subtle distinctions in the spatial distribution of pro-
299 arrhythmic fibrosis may exist between the two groups. While non-PV LA triggers have been identified
300 (posterior wall, appendage, mitral valve) (12), the PVs are considered the main source of focal activity
301 responsible for initiating AFib episodes (20, 21). In light of this fact, it is notable that our modeling
302 suggests triggered activity in the LPV and RPV regions is ~50% more likely to induce reentrant arrhythmia

303 in AFib vs. ESUS models (i.e., $IdS \approx 7.5$ vs. 5). An even more striking differential exists for the posterior
304 wall region, where the IdS score was $\sim 3x$ higher in AFib compared to ESUS models. This observation
305 suggests that even in the cases when common potential LA triggers, such as (i.e., PV or posterior wall
306 ectopy) do occur in ESUS patients, they are less likely to engage the fibrotic substrate and initiate
307 sustained reentry compared to the same activity in AFib patients. This possibility does not contradict our
308 hypothesis that the lack of arrhythmia in ESUS is due to a dearth of triggers; rather, it is a complementary
309 corollary that can be put to the test in future clinical and computational analysis.

310 While understanding of RD localization dynamics in AFib remains limited, evidence from ECGI
311 mapping indicates that reentrant activity occurs most frequently in the PV and posterior wall regions (15,
312 20, 21). Our findings are consistent with these data, with those same three areas harboring a majority
313 ($\sim 70\%$) of all observed RDs in models corresponding to AFib patients. In contrast, in the ESUS population
314 the atrial floor was the RD localization hotspot. The importance of this finding is unclear as tendencies
315 toward reentrant activity in particular LA areas has not been meaningfully correlated to clinical arrhythmia
316 properties. However, it provides a path for future validation studies: if incident AFib in patients who
317 previously presented with ESUS can be characterized by intracardiac mapping, the hypothesis that RDs
318 localize preferentially to the atrial floor can be tested.

319 Finally, across both ESUS and AFib cohorts we observed that LA regions with the highest IdS
320 generally corresponded to areas most likely to harbor RDs. The implication is that despite some
321 interesting and noteworthy trends in region-wise substrate susceptibility between ESUS and AFib, the
322 overarching conclusion of our analysis remains unchanged: we hypothesize that if the ESUS substrate
323 were subjected to suitable triggered activity, it would be fully capable of sustaining RDs indistinguishable
324 from those that perpetuate AFib.

325 **Limitations**

326 In this study, atrial tissue is modeled as a bilayer to drastically reduce computational load.
327 Previous studies have used this modeling framework (14, 22) to represent human atria effectively, but
328 the framework remains a simplification compared to volumetric 3D models. Moreover, clinical-grade MRI
329 resolution limits our ability to detect fine details in anatomical structure and spatial distribution of

330 potentially arrhythmogenic substrate, for instance slow-conducting tracks of fibrotic atrial tissue that could
331 underlie microreentrant circuits (23). While these models are patient-specific in terms of LA anatomy and
332 each individual's unique pattern of fibrotic remodeling, they do not incorporate inter-patient variability in
333 CV and electrophysiological properties such as ion channel expression. Nevertheless, our previous
334 analysis indicates that this representation of atrial architecture with generic "average AFib"
335 electrophysiology is appropriate for use in patient-derived modeling (10, 24).

336 As in previous studies (25, 26), our models do not differentiate between cell- or tissue-scale
337 properties of atrial electrophysiology between patients with paroxysmal and persistent forms of AFib.
338 Likewise, our approach to characterizing potential arrhythmia propensity in ESUS patients assumes cell-
339 and tissue-scale remodeling based on experimental and clinical data from the AFib milieu. Although this
340 is relevant as a limitation and must be considered when interpreting our results, this aspect of our
341 approach is also one of the major advantages of the modeling and simulation methodology. Specifically,
342 it allows us to assess whether there are any relevant differences in the spatial pattern of fibrotic
343 remodeling between ESUS and AFib patients in the absence of other potentially confounding variables.

344 Finally, the mechanism of stroke in ESUS patients may be independent of the presence of AFib
345 and atrial fibrosis through decreased atrial function might be a contributor to thrombus formation in the
346 absence of AFib. Currently, secondary stroke prophylaxis is dependent on detecting AFib and predicting,
347 through computational modeling, which atria are more prone to manifest AFib may be of clinical value.
348 Another future research direction that could prove highly fruitful in the near future would be to create
349 multi-scale, multi-physics image-based models of the fibrotic atria to assess each individual's risk of clot
350 formation in a patient-specific manner.

351 Conclusions

352 Simulations suggest that the pro-arrhythmic properties of fibrotic substrate in ESUS and AFib
353 patients are indistinguishable. Our results show that fibrotic remodeling in ESUS patients has the
354 theoretical capacity to sustain reentry when subjected to common AFib triggers. Thus, we conclude that
355 fibrotic substrate conducive to perpetuating reentry may exist in up to half of ESUS patients. As
356 individuals studied in this cohort present with incident AFib over the next few years, we will be able to put

357 this hypothesis to the test. Our findings also support the notion that the lack of AFib in this population
358 may be attributable to a lack of suitable arrhythmic triggers, but further research is needed to fully justify
359 this claim. While the existence of pre-clinical substrate is correlated with a higher global proportion of
360 fibrotic tissue, many ESUS cases defied these expectations, suggesting that fibrosis burden alone is
361 insufficient for predicting pre-clinical AFib substrate. This conclusion justifies the use of computational
362 simulations to probe beyond the fibrosis as imaged. Overall, these results provide novel insights into the
363 role of atrial fibrotic remodeling as a critical nexus between the otherwise distinct manifestations of AFib
364 and ESUS.

365 **Materials and Methods**

366 **Patient Population**

367 Patients were recruited to undergo cardiac LGE-MRI from the University of Washington (Seattle,
368 WA) and Klinikum Coburg (Coburg, Germany) between July 2016 and June 2019. This study was
369 approved by the Institutional Review Board (IRB) of the University of Washington (UW) and the
370 Ethikkommission der Bayerischen Landesärztekammer München, Bayern, Deutschland; all participants
371 provided written informed consent. Patients with ESUS met published diagnostic criteria (27). Patients
372 with paroxysmal (27/45, 60%) or persistent AFib and without stroke were recruited from the UW Cardiac
373 Arrhythmia Data Repository, an IRB-approved database for arrhythmia patients. Exclusion criteria for
374 AFib patients included those who had undergone LA catheter ablation before MRI and those with only
375 atrial flutter. Patients with cardiac implantable electronic devices, severe claustrophobia, renal
376 dysfunction, and other contraindications to MRI or gadolinium-based contrast were excluded.

377 **MRI acquisition**

378 Cardiac LGE-MRI was obtained on all participants to quantify the extent of LA fibrosis using
379 previously described protocols (11). Scans were performed on Philips Ingenia and Siemens Avanto
380 clinical scanners, 15 to 25 minutes after contrast injection, using a 3-dimensional inversion-recovery,
381 respiration-navigated, ECG-gated, gradient echo pulse sequence. Acquisition parameters included
382 transverse imaging volume with a voxel size of 1.25 x 1.25 x 2.5 mm (reconstructed to 0.625 x 0.625 x

383 1.25 mm). Scan time was 5 to 10 minutes dependent on respiration and heart rate. Fat saturation
384 sequences were used to suppress signal from fatty tissue.

385 **Reconstruction of 3D patient-derived atrial models from LGE-MRI**

386 Geometric models were reconstructed from LGE-MRI and the relative extent of fibrosis in the LA
387 was quantified via an adaptive histogram thresholding algorithm (28). Clinical-grade meshes (i.e., coarse
388 discretization) produced by Merisight Inc. (Salt Lake City, UT) were resampled with a target resolution of
389 200 μm using an automated process based on gmsh (29). Each LA model was represented as a bilayer
390 comprising of nested endocardial and epicardial shells, linked at every point by linear connections ($\sigma =$
391 0.8 S m^{-1}) (Fig. 1A). In each patient-derived model, realistic myocardial fiber orientations were mapped
392 from an atlas geometry (22) using the universal atrial coordinates (UAC) approach. Briefly, this process
393 assigned epicardial and endocardial fibers from a previously published bilayer model to the target atrial
394 geometry (Fig. 1B) (30, 31). In all finite element LA meshes, the average element edge length was
395 $\sim 188 \mu\text{m}$ and the number of nodes ranged from $\sim 600,000$ to ~ 1.4 million, depending on LA size. This
396 mesh resolution is consistent with previously established benchmarks for minimizing numerical error due
397 to spatial discretization in simulations of cardiac wavefront propagation (32).

398 **Modeling of atrial electrophysiology in fibrotic and non-fibrotic regions**

399 Our methodology for computational modeling at the cell and tissue scale of the fibrotic and non-
400 fibrotic atrial electrophysiology can be found in previously published papers (5, 15, 19). Briefly, in non-
401 fibrotic regions, a human atrial action potential model (33) was used to represent membrane kinetics,
402 including parameter modifications to fit clinical monophasic action potential recordings from AFib patients
403 (I_{Kur} , I_{to} , I_{CaL} decreased by 50%, 50%, 70%, respectively) (5, 34). At the tissue scale, non-fibrotic atrial
404 tissue, conductivity tensor values (longitudinal: $\sigma_L = 0.409 \text{ S m}^{-1}$; transverse: $\sigma_T = 0.08195 \text{ S m}^{-1}$) were
405 calibrated to obtain effective conduction velocity (CV) values of 71.49 cm s^{-1} and 37.14 cm s^{-1}
406 (longitudinal and transverse). These conductivities were chosen to match, CV values measured in AFib
407 patients ($61 \pm 6 \text{ cm/s}$) (35). In fibrotic regions, modifications to the AFib-like action potential model (I_{CaL} ,
408 I_{Na} , and I_{K1} decreased by 50%, 40%, 50%, respectively) were implemented as in prior studies (5, 36),
409 resulting in a 15.4% increase in action potential duration and a 49.6% decrease in upstroke velocity.

410 These changes represented the effect of elevated transforming growth factor- β 1, a key component of the
411 fibrogenic signaling pathway. As in previous studies (5, 15, 19), tissue-scale effects of interstitial fibrosis
412 and gap junction remodeling were represented by reducing overall conductivity and exaggerating the
413 anisotropy ratio ($\sigma_L:\sigma_T$) from 5:1 to 8:1 ($\sigma_L = 0.17708 \text{ S m}^{-1}$; $\sigma_T = 0.022135 \text{ S m}^{-1}$).

414 **Simulation of electrical activity and numerical aspects**

415 Electrical propagation in LA models was simulated by solving the monodomain equation using
416 the finite element method. This system was coupled with ordinary differential and algebraic equations
417 representing myocyte membrane dynamics at each node in the mesh, as described in the prior section.
418 All simulations were executed on the Hyak supercomputer system at the University of Washington using
419 the CARP software package (37, 38). A free version of CARP is available for academic use (see:
420 <https://openCarp.org>). The compute time required to complete each unique simulation ranged from 1-10
421 hours. The total CPU time for all simulations conducted in all models was 13.4 years.

422 **Induction and analysis of reentrant atrial arrhythmias**

423 Simulations were performed to assess the pro-arrhythmic propensity of the fibrotic substrate in
424 each patient-derived model. Arrhythmia induction via rapid pacing was attempted from 15 pacing sites
425 derived from AFib trigger sites (Fig. 1C, see caption for detailed anatomical site descriptions) (12).
426 Clinically relevant AFib trigger sites were chosen over a random pacing schematic to specifically capture
427 RDs that arise from locations demonstrated to induce AFib. Similar to previous publications, a clinically
428 relevant pacing sequence of 12 electrical stimuli was delivered at each of the 15 locations (5, 36).
429 Individual cell-scale ionic models were paced to steady-state at a rate basic cycle length of 500 ms. The
430 electrical stimulus consisted of two initial pulses with a coupling interval of 300ms, followed by pulses
431 ramping down to 200ms in 20ms intervals. After the delivery of the final stimulus, simulations were
432 monitored for self-sustaining electrical wavefront propagation. For all cases in which activity persisted for
433 at least 5,000ms post-pacing, we applied further analysis to determine whether the cause was an induced
434 RD or macroscopic re-entry (i.e. continuous repetitive, self-sustaining activation propagating around a
435 non-conductive obstacle such as the mitral valve or pulmonary vein(s)), which we consider flutter-like
436 reentry. Instances of macroscopic re-entry were excluded from further analysis.

437 For each AFib-inducible simulation, we documented whether each pacing site induced reentry
438 and analyzed patterns of RD localization. Unique RD morphologies in each patient-derived model were
439 classified as being located in one of five anatomical regions (Fig. 1D). These regions were delineated
440 automatically in a two-step process summarized in Supplemental Fig. 1. First, the LA was subdivided into
441 three broad anatomical areas (region 1: LA floor, 2: posterior wall; 3: anterior wall including LAA) using
442 standardized cutoff values in the UAC space (30). Second, the left and right PV areas (regions 4 and 5,
443 respectively) were established using a region-growing approach such that each accounted for 15% of
444 the total LA surface area. We then defined region-wise inducibility scores (IdS) across all models in a
445 particular group (ESUS or AFib) as the proportion of pacing sites within a given region from which rapid
446 pacing resulted in initiation of an RD. For example, since the LPV region contains four pacing sites
447 (anterior/posterior LSPV/LIPV), the corresponding ESUS IdS value would be derived by summing the
448 number of instances in which pacing from those locations induced RD across inducible ESUS models
449 then dividing by four. This ensured our ability to assess spatial heterogeneity of sensitivity to triggered
450 activity in a manner that was unbiased to the relative abundance of pacing sites in some LA regions.

451 **Statistical Analysis**

452 LA models for ESUS and AFib patients were divided into quartiles based on the extent of fibrotic
453 remodeling as measured by LGE-MRI. Continuous variables were compared pairwise between groups
454 using Wilcoxon rank-sum tests and were reported as mean \pm standard deviation. Confidence intervals
455 were calculated as the interval for the true difference in mean with 95% certainty. Categorical variables
456 were compared using a χ^2 test. After classifying unique RDs and number of pacing sites that induced
457 reentry, correlation with fibrosis was assessed with logistic regression. Statistical significance was
458 established at two-tailed $P \leq 0.05$. All statistical analysis was performed using R (39).

459

460 **Author Contributions:** SFB, NA, and PMB designed the study; SFB, GDS, and PMB built models, conducted
461 simulations, and analyzed computational results; CHR and SAN provided their implementation of the UAC
462 methodology and expertise on how to use it in model reconstruction; CM, PK, MM, and NA were responsible for
463 acquisition of cardiac LGE-MRI data; SS, ZB, CM, PK, MM, DT, WTL, and NA analyzed clinical data; SFB, NA, and
464 PMB wrote the manuscript with feedback from all co-authors.

465 **Acknowledgments:** SFB is supported by a fellowship from the ARCS foundation. CHR is supported by a Medical
466 Research Council Skills Development Fellowship (MR/S015086/1). SAN is supported by NIH R01-HL152256, ERC
467 PREDICT-HF (864055), BHF (RG/20/4/34803), EPSRC (EP/P01268X/1), and the Wellcome Trust (203148/Z/16/Z).
468 DT and WTL are co-PIs for the ARCADIA trial (NIH 5-U01-NS095869), which receives in-kind study drug from the
469 BMS-Pfizer Alliance and ancillary funding from Roche Diagnostics. NA is supported by John Locke Charitable Trust.

470

471 References


- 472 1. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation:
473 relationships among clinical features, epidemiology, and mechanisms. *Circ Res.* 2014;114(9):1453-68.
- 474 2. Israel C, Kitsiou A, Kalyani M, Deelawar S, Ejangue LE, Rogalewski A, et al. Detection of atrial fibrillation
475 in patients with embolic stroke of undetermined source by prolonged monitoring with implantable loop recorders.
476 *Thromb Haemost.* 2017;117(10):1962-9.
- 477 3. Brachmann J, Morillo CA, Sanna T, Di Lazzaro V, Diener HC, Bernstein RA, et al. Uncovering Atrial
478 Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients: Three-Year Results From the
479 Cryptogenic Stroke and Underlying Atrial Fibrillation Trial. *Circ Arrhythm Electrophysiol.* 2016;9(1):e003333.
- 480 4. Tandon K, Tirschwell D, Longstreth WT, Jr., Smith B, Akoum N. Embolic stroke of undetermined source
481 correlates to atrial fibrosis without atrial fibrillation. *Neurology.* 2019;93(4):e381-e7.
- 482 5. Zahid S, Cochet H, Boyle PM, Schwarz EL, Whyte KN, Vigmond EJ, et al. Patient-derived models link re-
483 entrant driver localization in atrial fibrillation to fibrosis spatial pattern. *Cardiovasc Res.* 2016;110(3):443-54.
- 484 6. Boyle PM, Zghaib T, Zahid S, Ali RL, Deng D, Franceschi WH, et al. Computationally guided personalized
485 targeted ablation of persistent atrial fibrillation. *Nat Biomed Eng.* 2019;3(11):870-9.
- 486 7. Roney CH, Beach ML, Mehta A, Sim I, Corrado C, Bendikas R, et al. In silico comparison of left atrial
487 ablation techniques that target the anatomical, structural and electrical substrates of atrial fibrillation. *Front*
488 *Physiol.* 2020.
- 489 8. Xia Y, Hertervig E, Kongstad O, Ljungstrom E, Platonov P, Holm M, et al. Deterioration of interatrial
490 conduction in patients with paroxysmal atrial fibrillation: electroanatomic mapping of the right atrium and coronary
491 sinus. *Heart Rhythm.* 2004;1(5):548-53.
- 492 9. Litchenberg WH, Norman LW, Holwell AK, Martin KL, Hewett KW, Gourdie RG. The rate and anisotropy
493 of impulse propagation in the postnatal terminal crest are correlated with remodeling of Cx43 gap junction pattern.
494 *Cardiovasc Res.* 2000;45(2):379-87.
- 495 10. Hakim JB, Murphy MJ, Trayanova NA, Boyle PM. Arrhythmia dynamics in computational models of the
496 atria following virtual ablation of re-entrant drivers. *Europace.* 2018;20(suppl_3):iii45-iii54.
- 497 11. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al. Association of atrial tissue
498 fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. *JAMA.*
499 2014;311(5):498-506.
- 500 12. Santangeli P, Marchlinski FE. Techniques for the provocation, localization, and ablation of non-pulmonary
501 vein triggers for atrial fibrillation. *Heart Rhythm.* 2017;14(7):1087-96.

- 502 13. Panfilov AV. Is heart size a factor in ventricular fibrillation? Or how close are rabbit and human hearts?
503 Heart Rhythm. 2006;3(7):862-4.
- 504 14. Roney CH, Bayer JD, Zahid S, Meo M, Boyle PM, Trayanova NA, et al. Modelling methodology of atrial
505 fibrosis affects rotor dynamics and electrograms. *Europace*. 2016;18(suppl 4):iv146-iv55.
- 506 15. Boyle PM, Hakim JB, Zahid S, Franceschi WH, Murphy MJ, Vigmond EJ, et al. Comparing Reentrant
507 Drivers Predicted by Image-Based Computational Modeling and Mapped by Electrocardiographic Imaging in
508 Persistent Atrial Fibrillation. *Front Physiol*. 2018;9:414.
- 509 16. Cochet H, Dubois R, Yamashita S, Al Jefairi N, Berte B, Sellal JM, et al. Relationship Between Fibrosis
510 Detected on Late Gadolinium-Enhanced Cardiac Magnetic Resonance and Re-Entrant Activity Assessed With
511 Electrocardiographic Imaging in Human Persistent Atrial Fibrillation. *JACC Clin Electrophysiol*. 2018;4(1):17-29.
- 512 17. Campanari L, You MJ, Langfield P, Glass L, Shrier A. Varieties of reentrant dynamics. *Chaos*.
513 2017;27(4):041101.
- 514 18. Cheng J, Scheinman MM. Acceleration of typical atrial flutter due to double-wave reentry induced by
515 programmed electrical stimulation. *Circulation*. 1998;97(16):1589-96.
- 516 19. Boyle PM, Hakim JB, Zahid S, Franceschi WH, Murphy MJ, Prakosa A, et al. The Fibrotic Substrate in
517 Persistent Atrial Fibrillation Patients: Comparison Between Predictions From Computational Modeling and
518 Measurements From Focal Impulse and Rotor Mapping. *Front Physiol*. 2018;9:1151.
- 519 20. Haissaguerre M, Hocini M, Denis A, Shah AJ, Komatsu Y, Yamashita S, et al. Driver domains in
520 persistent atrial fibrillation. *Circulation*. 2014;130(7):530-8.
- 521 21. Tanaka K, Zlochiver S, Vikstrom KL, Yamazaki M, Moreno J, Klos M, et al. Spatial distribution of fibrosis
522 governs fibrillation wave dynamics in the posterior left atrium during heart failure. *Circ Res*. 2007;101(8):839-47.
- 523 22. Labarthe S, Bayer J, Coudiere Y, Henry J, Cochet H, Jais P, et al. A bilayer model of human atria:
524 mathematical background, construction, and assessment. *Europace*. 2014;16 Suppl 4:iv21-iv9.
- 525 23. Hansen BJ, Zhao J, Li N, Zolotarev A, Zakharkin S, Wang Y, et al. Human Atrial Fibrillation Drivers
526 Resolved With Integrated Functional and Structural Imaging to Benefit Clinical Mapping. *JACC Clin
527 Electrophysiol*. 2018;4(12):1501-15.
- 528 24. Deng D, Murphy MJ, Hakim JB, Franceschi WH, Zahid S, Pashakhanloo F, et al. Sensitivity of reentrant
529 driver localization to electrophysiological parameter variability in image-based computational models of persistent
530 atrial fibrillation sustained by a fibrotic substrate. *Chaos*. 2017;27(9):093932.
- 531 25. Ali RL, Hakim JB, Boyle PM, Zahid S, Sivasambu B, Marine JE, et al. Arrhythmogenic propensity of the
532 fibrotic substrate after atrial fibrillation ablation: a longitudinal study using magnetic resonance imaging-based
533 atrial models. *Cardiovasc Res*. 2019;115(12):1757-65.
- 534 26. Shade JK, Ali RL, Basile D, Popescu D, Akhtar T, Marine JE, et al. Preprocedure Application of Machine
535 Learning and Mechanistic Simulations Predicts Likelihood of Paroxysmal Atrial Fibrillation Recurrence Following
536 Pulmonary Vein Isolation. *Circ Arrhythm Electrophysiol*. 2020;13(7):e008213.
- 537 27. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic Stroke of Undetermined Source: A
538 Systematic Review and Clinical Update. *Stroke*. 2017;48(4):867-72.

- 539 28. Jadidi AS, Cochet H, Shah AJ, Kim SJ, Duncan E, Miyazaki S, et al. Inverse relationship between
540 fractionated electrograms and atrial fibrosis in persistent atrial fibrillation: combined magnetic resonance imaging
541 and high-density mapping. *J Am Coll Cardiol*. 2013;62(9):802-12.
- 542 29. Geuzaine C, Remacle J-F. Gmsh: A 3-D finite element mesh generator with built-in pre- and post-
543 processing facilities. *International Journal for Numerical Methods in Engineering*. 2009;79(11):1309-31.
- 544 30. Roney CH, Pashaei A, Meo M, Dubois R, Boyle PM, Trayanova NA, et al. Universal atrial coordinates
545 applied to visualisation, registration and construction of patient specific meshes. *Med Image Anal*. 2019;55:65-75.
- 546 31. Roney CH, Bendikas R, Pashakhanloo F, Corrado C, Vigmond EJ, McVeigh ER, et al. Constructing a
547 Human Atrial Fibre Atlas. *Ann Biomed Eng*. 2020.
- 548 32. Niederer SA, Kerfoot E, Benson AP, Bernabeu MO, Bernus O, Bradley C, et al. Verification of cardiac
549 tissue electrophysiology simulators using an N-version benchmark. *Philos Trans A Math Phys Eng Sci*.
550 2011;369(1954):4331-51.
- 551 33. Courtemanche M, Ramirez RJ, Nattel S. Ionic mechanisms underlying human atrial action potential
552 properties: insights from a mathematical model. *Am J Physiol*. 1998;275(1):H301-21.
- 553 34. Krummen DE, Bayer JD, Ho J, Ho G, Smetak MR, Clopton P, et al. Mechanisms of human atrial
554 fibrillation initiation: clinical and computational studies of repolarization restitution and activation latency. *Circ*
555 *Arrhythm Electrophysiol*. 2012;5(6):1149-59.
- 556 35. Konings KT, Kirchhof CJ, Smeets JR, Wellens HJ, Penn OC, Allessie MA. High-density mapping of
557 electrically induced atrial fibrillation in humans. *Circulation*. 1994;89(4):1665-80.
- 558 36. Zahid S, Whyte KN, Schwarz EL, Blake RC, 3rd, Boyle PM, Chrispin J, et al. Feasibility of using patient-
559 specific models and the "minimum cut" algorithm to predict optimal ablation targets for left atrial flutter. *Heart*
560 *Rhythm*. 2016;13(8):1687-98.
- 561 37. Vigmond EJ, Hughes M, Plank G, Leon LJ. Computational tools for modeling electrical activity in cardiac
562 tissue. *J Electrocardiol*. 2003;36 Suppl:69-74.
- 563 38. Vigmond EJ, Weber dos Santos R, Prassl AJ, Deo M, Plank G. Solvers for the cardiac bidomain
564 equations. *Prog Biophys Mol Biol*. 2008;96(1-3):3-18.
- 565 39. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R
566 Foundation for Statistical Computing; 2019.
- 567
- 568

569 Supplemental Information

570



571

572 **Supplemental Figure 1. LA subdivision scheme.** (A) Alpha coordinate from universal atrial coordinate
573 (UAC) system mapped on to a representative LA model. (B) Beta coordinate from UAC mapped on to a
574 representative LA model. (C) 2D representation of UAC with pulmonary vein locations labeled. Dashed
575 lines represent edges of the five atrial regions. (D) Segmented LA mapped onto a 3D mesh with
576 numbered regions corresponding to regions in (C). (E) Final division scheme after edge expansion of the
577 LPVs and RPVs to generate regions 3 and 4 respectively.

578

579 **Supplemental Video 1. Dynamic illustration of reentrant arrhythmia sustained by dual**
580 **simultaneous RDs.** The video shows membrane voltage over time for the same episode of induced
581 arrhythmia highlighted in Fig. 5 and discussed in the main text.